CHEMICAL TECHNOLOGY

We can solve the plastic waste crisis but we don’t have much time

JOHN RICHARDSON | May 27, 2021

article image
IN 2015, a global agreement was reached that 8m tonnes a year of plastic waste entering the oceans was unacceptable, according to this September 2020 article in The Conversation. This was the amount of plastic that  was estimated to have ended up in the oceans in 2010.

“Several international platforms emerged to address the crisis, including Our Ocean, the UN Sustainable Development Goals and the G7 Ocean Plastic Charter, among others,” continued the article.

But in 2020, an estimated 24m-34m tonnes of plastic waste was forecast to enter our lakes, rivers and oceans. This could reach as much as 90m tonnes in 2030 if the current trajectory continued, said The Conversation.

This is the type of information out there, free to view on the internet and accessible via a very quick Google search, representing a major challenges for our industry. I cannot of course verify the numbers. But they are out there.

Also out there is a May 2019 article by the World Economic Forum (WEF), which provided a good summary of research into what experts believed was the scale of the waste problem in the developing world.

Spotlight

Seattle Genetics

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

OTHER ARTICLES

COVID-19: Managing disruption in the chemical industry

Article | March 30, 2020

The chemical industry is no stranger to disruption, from SARS to trade policy conflict and the financial crisis. Yet COVID-19 is unprecedented in its impact, creating a universal imperative for governments and businesses to take immediate action to protect their people. Unlike many other sectors, the chemical industry is not in a position to stop production and send workers home. Instead, it needs to strike the right balance between “social distancing” and keeping plants running to provide the basic necessities for society, as well as the antiseptics, disinfectants, protective packaging and more needed to fight the pandemic.

Read More

THE BENEFITS OF CHEMICAL FOAMERS, AND HOW BEST TO USE THEM TO MAXIMISE PRODUCTION

Article | March 30, 2020

Downhole fluid build-up coupled with a drop in reservoir pressure can lead to the rapid decline of gas production rates, and can ultimately result in a well ceasing production. While there are many ways to deliquify a well to maximise production, chemical foamers can be incredibly effective and well worth considering. In this blog post, Kevin Lonie shares some of the benefits of using chemical foamers, and provides insights and advice around how best to use them… “Foamers are a much cheaper option than alternative solutions, such as mechanical lifts, and there is very little risk associated with their usage. If a foamer doesn’t work, it won’t make the well worse - so often we see clients giving them a go before opting for more expensive methods, in the hope that they produce the desired results. And we have seen their success over and over again.”

Read More

Why QuickStart Chemical Management Can Save Your Assets

Article | March 30, 2020

The world of Environmental, Health and Safety (EHS) IT systems is a vast one. Therefore, it cannot be stressed enough that organizations need to be nimble and armed with easy-to-deploy, interoperable, portable systems. Most mature organizations opt for a risk-based EHS management system framework designed to meet a continually evolving and dynamic business and operating model. A risk-based approach offers flexibility, within defined boundaries, for alternate solutions to risk management needs. Standard frameworks recommend mandatory controls when there is potential for high-consequence events. Moreover, risk control measures which have been proven effective and considered technically superior are increasingly used.

Read More

What Are Fine Chemicals?

Article | March 30, 2020

The initial versions of drugs were produced by extracting substances from natural herbs and other plants. As understanding and technology in chemistry continued to grow, scientists figured out to isolate and extract a lot more individual compounds from raw materials. The complicated processes that produce these simple, pure substances form the field of fine chemistry. The chemical industry is separated into branches, with fine chemicals serving as the smallest segment of them. Its companions are commodities and specialty chemicals. Commodity chemicals are those that are mass-produced on a big scale to supply global markets. They include general compounds that are the same from supplier to supplier. Specialty chemicals usually are sold as brand name products and are advertised for their distinct qualities and their abilities to carry out functions that other chemicals cannot. They are composed of one or more fine chemicals.

Read More

Spotlight

Seattle Genetics

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

Events